Navigation Links
Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
Date:11/27/2007

s as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employee's performance and value to PPD contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5890


SOURCE PPD, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Halozyme Therapeutics, ... Update Conference Call for the second quarter 2015 on ... PT. Dr. Helen Torley , president and chief ... date post-market, Halozyme will release financial results for the ... webcast live through the "Investors" section of Halozyme,s corporate ...
(Date:8/3/2015)... 3, 2015  Merck KGaA, Darmstadt, Germany ... high-tech products in the healthcare, life science and performance ... Nano-C, their development and launch of promising new fullerene ... Merck KGaA, Darmstadt, Germany , is ... sector. Novel derivatives: highly stable, easy to ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Prevalence and Roles of miRNAs , ... cloned , and sequenced from human ... apparently regulates multiple genes, and miRNAs are thought to , ... predict mRNA target sites for miRNAs [2,3]. A handful of these , ...
... Construction Kit , Prepare your probe in ... Ideal for siRNA/miRNA studies , ... high specific , activity RNA probes for RPA, Northern, Southern, ... No cloning required , ...
... , with a fluorometer capable of ... ultra-sensitive assay for determining RNase A specific activity. The , ... including RNase A, T1, RNase I, micrococcal ... nuclease, and Benzonase. In addition to detecting , ...
Cached Biology Technology:Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 2Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 3Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 5Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 6Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 7Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 8Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 9Prepare siRNA and miRNA Probes in Just 1 Hour 2Prepare siRNA and miRNA Probes in Just 1 Hour 3Measuring RNase Activity A Real-time Kinetic Analysis 2Measuring RNase Activity A Real-time Kinetic Analysis 3Measuring RNase Activity A Real-time Kinetic Analysis 4Measuring RNase Activity A Real-time Kinetic Analysis 5
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... period of torpor to conserve energy when resources are scarce. ... champion by far among vertebrates is the burrowing frog ( ... in the mud in the absence of any food or ... scientists at the University of Queensland have discovered that the ...
... new arsenal for meningitis treatment and the war on ... developed by scientists at the Institute of Bioengineering and ... Nanotechnology . The stable bioengineered nanoparticles devised at ... cells that could cause fatal infections and are highly ...
... new song from a member of its own species, the experience ... The sequential switching on and off of thousands of genes after ... memory in the songbird brain. The finding, detailed this month ... was a surprise, said principal investigator David Clayton, a professor of ...
Cached Biology News:Super-sleepers could help super-sizers! 2Singapore nanotechnology combats fatal brain infections 2Researchers see evidence of memory in the songbird brain 2
... combines 2 products into 1:, , A ... isolation kit , ,The FastPrep System ... Qbiogene/BIO101 System Matrix and Isolation Kits. Samples ... tubes eliminating the use of metal probes ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Sterile, individually wrapped, 4mm Cuvettes...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: